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It is believed that tumor development, outgrowth and metastasis are under the surveillance of the
immune system. Although both innate and acquired immune systems play roles, innate immunity is
the spearhead against tumors. Recent studies have revealed the critical role of natural killer (NK) cells
in immune surveillance and that NK cell activity is considerably influenced by various agents, such as
environmental factors, stress, foods and drugs. Some of these NK cell stimulants have been used in
complementary and alternative medicine (CAM) since ancient times. Therefore, the value of CAM
should be re-evaluated from this point of view. In this review, we overview the intimate correlation
between NK cell functions and CAM agents, and discuss possible underlying mechanisms mediating
this. In particular, neuro-immune crosstalk and receptors for CAM agents are the most important and
interesting candidates for such mechanisms.
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Introduction
It has been well known since ancient times that complemen-
tary and alternative medicine (CAM), including exercise,
provides a lot of benefit to health. Many CAM modalities
are believed to prevent or even cure diseases, especially morbid
ones such as cancer. However, until recently conventional
medicine has largely rejected the use of CAM agents because
little biological evidence has been provided for the functional
mechanisms of many of them. For the past few decades, the
value of CAM has been rediscovered by many modern scien-
tific researchers. Modulation of immune functions by CAM
agents is the mechanism most widely analyzed and has been
suggested to provide some scientific evidence for the biologi-
cal effects of various CAM agents. Specifically, evidence for
up-regulation of natural killer (NK) cell numbers and/or NK
cell cytotoxicity by these agents has been accumulating. NK
cells have been well established as innate cytotoxic effector
cells for self defense in both vertebrates and invertebrates, in
both of which they may use similar mechanisms in the lysis of
target cells (1). In this review we overview NK cell functions
and their functional molecules, particularly in relation to
cancer, and discuss the possible mechanisms of NK cell
activation by various CAM agents.
Why are NK Cells Important?
Ever since Lewis Thomas and Macfarlane Burnet proposed
the immune surveillance hypothesis against tumor develop-
ment, the concept has been a hot focus of debate for more
than 40 years (2,3). The original immune surveillance
hypothesis was challenged because nude mice lacking T cells
did not show a higher incidence of cancer than did syngenic
immunocompetent mice (4). However, this contradictory
conclusion is now taken as fine evidence that innate immu-
nity is in the critical arms of immune surveillance against
tumor development. Moreover, in the innate immune system
NK cells, which do not express T-cell receptors that recognize
specific peptides presented on the major histocompatibility
complex (MHC), rather than T cells, seem well suited for this
role. NK cells thus mediating natural cytotoxicity are com-
posed predominantly of large granular lymphocytes (LGL)
and some of small agranular lymphocytes, both of which
express CD16 and CD56, but no T-cell receptor, on the cell
surface (5,6). NK cells can induce cytolysis in the absence of
MHC class I antigen expression on their target cells (5). This
phenomenon is commonly understood according to the
‘missing self’ hypothesis (7). Culture of NK cells with some
cytokines augments their cytotoxic activity so that they
become able to induce cytolysis for a wide spectrum of cells,
including tumor cells expressing autologous MHC class I.
They are now called lymphokine-activated killer (LAK) cells,
although LAK cells are also induced by T lymphocytes (8–
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NK Cells and Cancer
Tumor Immunosurveillance by NK Cells in Animal 
Models
Animals with low levels of NK cell activity (beige, cyclophos-
phamide or anti-asialo GM1 antibody-treated mice) have
been shown to develop an increased number of spontaneous
and experimental tumors and their metastases (11–13). Con-
versely, animals with augmented NK cell activity (treated with
corynebacterium parvum or IFN-inducer) display increased
resistance to the development of metastasis (14). Adoptive
transfer of splenocytes with high NK cell activity partially
restored the anti-metastatic ability of anti-asialo GM1 and
cyclophosphamide-treated animals (12,15). Direct evidence
for the role of LGL in the prevention of blood-born metas-
tases was demonstrated by the inhibition of experimental
metastases in NK cell-deficient mice following adoptive
transfer of LGL (16,17).
Tumor Immunosurveillance by NK Cells in Humans
Despite relevant evidence from animal studies, the role of NK
cells in immunologic surveillance against cancer in humans is
poorly defined. Circumstantial evidence for the crucial role
of natural cytotoxicity in human cancer was obtained by
studying patients with NK deficient states. Patients who have
Chëdiak–Higashi syndrome (18), X-linked lymphoprolifera-
tive syndrome (19) or who have had renal transplants (20) all
have reduced NK cell activity and an increased incidence of
cancer. Various studies have shown peripheral blood NK cell
activity to be significantly reduced in patients with cancer
compared with non-cancer-bearing control subjects (21–23).
Other researchers, however, have documented no reduction
in NK cell activity in patients with some cancers, irrespective
of the stage of the disease (24,25). Thus, the precise role of
NK cell cytotoxicity in human cancer remains inconclusive.
Overall, however, there appears to be a trend for NK cell
activity to be reduced in certain tumors, possibly related to
tumor volume or dissemination. Some studies reported an
increased risk of developing cancer in individuals with low
NK cell activity, and normal NK cell activity only in the early
stage of cancer (21,26–28). Several groups have reported
increased blood-born metastasis, significantly increased risk
of death from uncontrolled regional and distant metastasis,
the development of regional and distant metastasis and risk
of local recurrence in patients with low NK cell activity (29–
33). Moreover, one epidemiological study recently indicated
that low NK cell activity is associated with increased cancer
risk, although it is premature to conclude from this result that
NK cell activation induces tumor prevention (34). However,
even this report can not be taken as clear evidence for NK
cell-dependent tumor surveillance in humans, since expres-
sion of MHC class I, the most critical molecules for suscepti-
bility to NK cell activity, on developing tumors was not
analyzed.
We suggest that natural cytotoxicity mediated by NK cells
may have a role in the prevention of the development of can-
cer and in the establishment of metastasis in humans as well
Figure 1. NK cells in tumor surveillance. NK cells are activated by some cytokines and direct recognition of ligands of their NK cell activating receptors, which
result in direct tumor cell lysis through their cytotoxic molecules (peforin/granzyme, Fas ligand, TRAIL) and activation of other immune cells (macrophages
and T cells) through cytokine production. IFN-γ produced by NK cells also plays a critical role in the inhibition of angiogenesis by tumor development.eCAM 2004;1(1) 19
as mice, although more evidence at the molecular level needs
to be accumulated to define the role of NK cells in tumor
surveillance in humans. Moreover, further epidemiological
studies are needed to more precisely define whether NK cell
activity can predict further cancer development in patients at
high risk, or if NK cell activity has prognostic value in cancer
patients. An intriguing possibility is prevention and/or cure
of cancer by augmenting NK cells by CAM agents.
Cytotoxic Molecules of NK Cells and Tumors
Several studies have demonstrated an increased tumor inci-
dence in mice deficient in cytotoxic molecules. A higher
incidence of tumors has been noted in mice deficient in per-
forin (35,36), which is the critical cytotoxic molecule of NK
and cytotoxic T cells (37), and tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) (38,39). A higher
spontaneous and methylcholanthrene (MCA)-induced tumor
formation were also reported in STAT-1 [a signal molecule
require for responsiveness to interferons (IFNs)], IFN-γ-,
and IFN-γ receptor-deficient mice (40–43). These show that
impairment of the receptor for cytokines activating NK cells
results in defective immune surveillance against tumors.
Although these studies provide clear evidence for immune
surveillance, there have been few reports of exactly how the
tumor cells are recognized as abnormal and then eliminated.
Recent studies on NK cell receptors have indicated the possi-
ble receptors responsible for tumor recognition and thus pro-
vide new support for the hypothesis of NK cell-mediated
tumor surveillance (Fig. 1).
NK Cell Receptors for Tumor Recognition
The first NK cell receptors clearly defined were shown to bind
both classical and non-classical MHC class I molecules and
block the killing of target cells by NK cells (44). This inhibi-
tion was associated with immunoreceptor tyrosine-based
inhibitory motif (ITIM) domains in the cytoplasmic tails of
these NK receptors. ITIMs provide docking sites for phos-
phatases that oppose the activity of tyrosine kinases, which
are essential enzymes for NK cell activation. However, cer-
tain members of the NK receptor family, KIR2DS, Ly49D/H
and CD94/NKG2C, do not possess ITIMs. Instead, they are
associated with the adapter molecule DAP12, which has
an immunoreceptor tyrosine-based activating motif (ITAM)
domain capable of activating NK cells (44). Thus, the view is
now emerging that the activity of NK cells is regulated by the
balance between activating and inhibitory signals. However,
other than the down regulation of MHC class I molecules, it
has been unclear which other molecules are likely to tip the
balance in favor of NK cell activation for tumor surveillance
(Table 1).
The Role of NKG2D in Tumor Surveillance
NKG2D, encoded within the NK receptor gene complex,
might be the activating receptor of NK cells critical for
immune surveillance against tumors, since some NKG2D
ligands (MICA and MICB in human, Rae1 and H60 in mice)
can be induced by environmental stress and are expressed on
many tumor cells (45–47). Moreover, not only NK cells but T
cells expressing the γδ or αβ T cell receptor (TCR) express
NKG2D, thus NKG2D turns out to be the missing link and
unites innate and adoptive immunity in immune surveillance
and anti-tumor immunity. Presumably, tumor cells, once they
express NKG2D ligands, become able to induce immunologi-
cal tolerance against attack from NK cells, as they are highly
enhanced inhibitory ligands to be expressed.
CD94/NKG2A and CD94/NKG2C for Surveillance of 
‘Modified Self’
CD94/NKG2 is the other crucial receptor for NK cell-medi-
ated immune surveillance (44,48,49). HLA-E (Qa-1b in mice)
is the relatively non-polymorphic ligand of inhibitory CD94/
NKG2A and activating CD94/NKG2C. It has a preference
for nonameric peptide, derived from the signal sequence of
other class I molecules. Thus, CD94/NKG2A plays a critical
Table 1. Summary of known NK cell receptors
HLA, human leuocyte antigen; KIR, killer cell immunoglobulin-like recep-
tors; MCMV, mouse cytomrgalovirus; MIC, MHC class I-chain related mol-
ecules; RAE-1, retinoic acid early inducible 1; ULBP, UL-16-binding protein.
Species Receptor Ligands
Mice
Inhibitory Ly49 H-2K, H-2D
CD94/NKG2A Qa-1b
Activating CD16 IgG
NKp46 Influenza haemagglutin, others?
NKR-P1C ?
CD94/NKG2C Qa-1b
Ly49D H-2Dd
Ly49H MCMV-induced?
NKG2D RAE1, H60, Mult1
CD244 CD48
Human
Inhibitory KIR2DL
KIR3DL HLA-C
CD94/NKG2A(CD159a) HLA-Bw4, HLA-A
Activation CD85j, CD85d HLA-E
CD16 HLA ClassI
NKp30 IgG
NKp46 ?
KIR2DS Influenza hemagglutin, others?
KIR2DL HLA-C, others
CD94/NKG2C HL-G
NKp44 HLA-E
NKG2D Influenza hemagglutin, others?
CD244 MICA/MICB, ULBP
CD4820 CAM and NK cells
role in blocking NK cell cytotoxicity by classical and non-clas-
sical MHC class I molecules. It might also be the receptor
most likely to be responsible for the phenomenon explained
by the ‘missing self’ hypothesis: namely, loss of MHC class I
expression leads to sensitivity to lysis by NK cells (7). It was
recently reported that a peptide from the signal sequence of
stress protein hsp60 is loaded onto HLA-E, competing effec-
tively with an MHC class I-derived peptide, and up-regulates
surface expression of HLA-E (50). HLA-E loaded with the
hsp-derived peptide does not bind to CD94/NKG2A. There-
fore, stress-induced modification of HLA-E would activate
CD94/NKG2A-expressing NK cells due to loss of inhibitory
ligands, which would result in the augmentation of sensitivity
to NK cells on the part of cells expressing hsp60. ‘Modified
self’ (ligand modification of inhibitory receptor: CD94/
NKG2A,HLA-E) is another mechanism by which susceptibil-
ity of tumor cells to NK cells is augmented, in addition to the
‘missing self (reduced class I expression)’ and ‘induced self’
(expression of NKG2D ligands) mechanisms (51).
NK Cells and CAM
Activation of NK Cells by CAM Agents
For the past few decades, scientific investigations on CAM
have remarkably advanced and partly supported their
medical efficacy through preclinical and clinical experiments.
Such CAM modalities include: Oriental medicine, especially
traditional Chinese medicine (including Kampo and acu-
puncture), extract products from natural plants, animal
molecules and live lactic acid bacteria. In particular, many
investigators have suggested that NK cell activation is one of
the critical mechanisms for the biological effects induced by
various CAM agents. For example, intake of green tea and
some kind of live lactic acid bacteria enhanced NK cell
activity (52–54). Administration of extracts from ginseng
(52), aged garlic (55), Viscum album (mistletoe) (56,57),
Cichorium intybus (58), Echinacea purpurea root (59),
Derris scandens hydroalcholic (60), some wild plants (61),
Table 2. Summary of NK cell activation-inducing CAM
CAM Immunological effects
Green tea Humoral and cell-mediated immunity including NK cell activation
Ginseng Increase in macrophage, NK, T and B cells number
Vitamin supplementation Increase in antibody titer
Honey Increase in antibody titer
Lactobacillus casei strain Shirota  Increased NK cell activity
Extract
Aged garlic  Prevent a reduction of NK cell activity by psychological stress; prevent the decrease of spleen 
weight by psychological stress
Viscum album (mistletoe) Increased NK cell number and NK cell activity
Cichorium intybus Increase in circulating leukocytes; increase in phagocytic activity, NK cell activity, proliferation 
and IFN-α production
Echinaces purpurae root Increased NK cell activity
Derris scandens Increased NK cell activity in HIV-infected individuals
Nigella sativum seeds Increased NK cell activity
Allium sativum bulb Increased NK cell activity
Onopordum acanthium stem and leaves Increased NK cell activity
Allium cepa bulbs Increased NK cell activity
Chinese herb (e.g. Shikaron) Increased NK cell activity
Phyllanthus emblica Increased NK cell activity and antibody dependent cellular cytotoxicity (ADCC)
Mushrooms (e.g. Lentinus edodes and Agaricus blazei) Increased NK cell activity
Physiological
Acupuncture Increase in T cell and NK cell numbers; increase in monocyte phagocytosis
Electroacupancture Increased NK cell activity and IFN-α and IL-2 production
Skin rubdown Increased NK cell activity
Exercise (dependent on time and frequency) Increased NK cell activity and NK cell numbers
Psychological
Relaxation Increased NK cell activity and T cell response; increase in the number of peripheral blood 
lymphocytes
Message therapy Increase in NK cell number in HIV-infected individuals
Music therapy Increase in NK cell number and NK cell activity 
Mirthful laughter Prevents a reduction of NK cell activity by psychological stress; increased NK cell activity; 
increase in NK cells, T cells, immunoglobulins and IFN-α productioneCAM 2004;1(1) 21
Chinese herbs (62) and some kinds of mushrooms (63) sig-
nificantly augmented NK cytotoxicity or restored NK cell
activity in some immune-suppressive conditions. Some of
these agents showed inhibition of experimental metastasis of
cancer. Oral administration of Phyllanthus emblica, which is
known as an excellent source of vitamin C, enhanced NK
cell activity and antibody-dependent cellular cytotoxicity
(ADCC) (64), thus, supplemental nutriments might enhance
NK cell activity. Moreover, acupuncture (65,66), skin rub-
down (67), relaxation (68,69), message therapy (70), music
therapy (71), mirthful laughter (72,73) and hypnotherapy
(74) enhanced NK cell activity and/or NK cell numbers.
There are a considerable numbers of studies reporting that
acute and chronic exercise and long-term repeated exercise
(training effects) elevated NK cell activity in peripheral blood
(75–79) (Table 2).
Thus, numerous studies have reported the augmentation of
NK cell number and/or NK cell cytotoxicity by CAM agents
as described above. In order to examine this important issue
further, however, criteria for the quality of evidence need to
be established. It would not mean much, for example, if a
report only showed that a certain CAM agent increased the
number of NK cells in mice or humans.
A considerable number of reports have presented clinical
observations. However, large-scale epidemiological studies to
establish intimate correlations of any single CAM agent with
NK cells in any specific disease conditions (e.g. cancer) are
still lacking. Future epidemiological studies should be based
on sound biological experiments both in vitro and in vivo. In
selecting parameters for prospective epidemiological studies,
we would like to draw attention to the next point below, and
also the problem of individual differences between possible
‘CAM-agent receptors’ as shown in the following sections.
Without such biological considerations, epidemiological
analysis will be pointless.
It is now well known that NK cell activity is regulated by
expression levels of cytotoxic molecules, activating receptors
and/or inhibitory receptors. Thus, decrease or increase in NK
cell number in peripheral blood mononuclear cell (PBMC)
does not necessarily result in a decrease or increase in NK cell
activity, respectively. Therefore, in designing any further
experiments in this field, NK cell numbers and NK cell cyto-
toxicity should be analyzed simultaneously, and responsible
molecules or mechanisms for CAM effects should be clearly
defined.
Cytotoxic and activation mechanisms of NK cells have
been demonstrated in experimental models using various
gene-modified mice (transgenic and gene-knock-out mice).
Therefore, we recommend researchers to design experiments
using such laboratory mice. It should become the standard
preclinical system in which mechanisms of the effects of any
CAM agents in the activation of NK cells are to be clearly
demonstrated in vivo.
Example: NK Cell Activation by Lactobacillus casei Strain 
Shirota and Extract of Mushrooms
We have analyzed the effect on immunological function of a
fermented milk drink containing Lactobacillus casei strain
Shirota (LcS) (53). The frequency and the number of NK
cells, CD4+ T cells or CD8+ T cells were not significantly
changed, and T cell responsiveness to mitogens (Con A and
PHA) and allantigen stimulation were unchanged. Moreover,
significant increase of IFN-α and IFN-γ could not be
detected in serum at all. However, NK cell cytotoxicity was
significantly increased, and the enhancement of NK cell
activity was particularly prominent in the low NK activity
individuals (Fig. 2). We have also analyzed NK cell activity
after the intake of the extract of mushrooms, Agaricus blazei
and  Lentinus edodes, which are commonly used CAM
agents in Japan. Although intake of these extracts did not
induce significant change in lymphocyte populations and T
cell responses, NK cell activity was augmented. Notably, sus-
ceptibility to extract of Agaricus blazei was varied among
individuals; however, it was closely correlated to the respon-
siveness to the extract of Lentinus edodes but not LcS. This
suggests that these individuals are selectively susceptible to
some general components of the mushroom extracts (Table
3). Conversely, NK cell activity was highly augmented by LcS
but not the mushroom extracts in some volunteers, and only
slight augmentation of NK cell activity was observed by
either LcS or mushrooms extract in some others, even if their
NK cell activity was relatively low.
It has often been suggested that effects of some CAM
modalities are varied among individuals. Our examples pre-
sented above suggest that the individual differences in the
responsiveness to CAM agents may be due to the individual
difference of expression of various CAM receptors. If it really
is the case, it supports the concept that proper selection of
CAM agents for each individual is needed in order for their
effects to be manifested.
Figure 2. Intimate correlation between the magnitude of the increase in NK
cell activity and the level of NK cell activity. The increase in NK cell activity
after the intake of LcS drink is prominent in individuals with low NK cell
activity. The correlation was determined by Pearson’s methods; statistical
significance was P < 0.05.22 CAM and NK cells
How do CAM Agents Activate NK Cells?
The precise mechanisms of NK cell activation by CAM
agents have not been clearly defined. The two main possibili-
ties are: (i) augmentation of cytotoxic molecules in NK cells
and/or (ii) up-regulation of activating NK cell receptors and/
or down-regulation of inhibitory NK cell receptors. On the
other hand, improvement of general ‘health’ conditions by
some CAM agents, e.g. exercise, may result in NK cell activa-
tion, although precise pathways are still unclear. We shall dis-
cuss in this section two interesting mechanisms, one indirect
and the other direct, which seem to be reasonable explana-
tions for the NK cell activation induced by CAM agents.
Neuro-immune Crosstalk
A growing body of evidence shows a crucial role of the auto-
nomic nervous system in modulating the immune response
in stress (75). For example, the autonomic nervous system
might play an important role in the modulation of the
immune response after both acute and chronic exercise.
Intimate crosstalk between the central nerve systems and
the immune systems has been demonstrated by experiments
using electrical stimulation of the ventromedial horn of the
hypothalamus, which is the site in the central nervous system
responsible for delivering sympathetic stimulus to spleen
(80,81). There is also evidence to show a crucial role of the
autonomic nervous system in modulation of the immune
response, especially under the influence of stressors and
exercise (82,83), although little is known about the role of
parasympathetic nerves compared to the large amount of
information available on sympathetic nerves in immune
regulation.
Modulation of the immune response can be mediated
either through innervation by sympathetic nerves or through
the receptors for their chemical transmitters on immune cells
in these organs, as described below.
Regulation of Blood Flow by the Sympathetic Nervous
System—An important role of autonomic nerves in both pri-
mary and secondary lymphoid organs was reported for the
regulation of blood flow (81,84,85), which plays a major role
in immune regulation by facilitating the right cells to lodge or
move to where they can efficiently accomplish their task
(86,87).
Direct Effects of the Sympathetic Nervous System on
Immune Cells—A growing number of studies suggests that
sympathetic nerves can influence immune cells more directly
than just by regulating the blood flow. Catecholamines
released from sympathetic terminals are major mediators
responsible for immune regulation when they bind to their
specific receptors (88). Their suppressive nature on NK cell
cytotoxicity has been reported (89,90). In striking contrast,
acute deprivation of sympathetic innervation causes
enhancement, while its chronic deprivation seems to cause
suppression, of NK cell activity, and diminished cell-mediated
immunity (91,92).
Impact of Sympathetic Modulation on the Distribution of
Leukocytes—An active involvement of autonomic regulation
in leukocyte distribution is suggested by the following fact.
The increase in circulating NK cells and decreased NK cell
attachment to endothelial cells induced by catecholamines
but independent of adhesion-molecules, was inhibited by
β2-adrenergic antagonist (93–95). NK cells have higher
expression of β-adrenergic receptors and lower expression of
cholinergic receptors, and are thereby influenced by sym-
pathetic and parasympathetic activities (96). Mental stress
accompanied by sympathetic activation increases the number
of NK cells in circulation, which is blocked by β-adrenergic
antagonist (93,97,98). In the same study it was demonstrated
that spleen does not serve as a pool for NK cells (93). On the
other hand, an increased accumulation of catecholamine-
stimulated lymphocytes to secondary lymphoid organs might
account for the transient decrease in lymphocytes from circu-
lation after catecholamine injection (99). Thus, the origin of
NK cells released into circulation after β-adrenergic stimula-
tion is an open question yet to be answered.
Taken together, the sympathetic nervous system does not
simply suppress the immune system but might help in organ-
izing the immune response sequentially and spatially by
modulating the distribution of immune cells. Modification of
blood flow and cell adhesion must be the crucial event for
increasing NK cells in peripheral blood by CAM agents, since
increase of NK cell numbers does not always link to augmen-
tation of NK cell cytotoxicity (Fig. 3).
Table 3. Intimate correlation of susceptibility to extracts of mushrooms
*++, 20% or more increase of NK cell cytotoxicity at E/T = 20; +, around 10% increase in NK cell cytotoxicity at E/T =
20.
Agaricus blazei* Lentinus edodes* Lactobacillus casei strain Shirota Population
Group A ++ ++ various 25%
Group B + + various 50%
Group C – – various 25%
Group D ++ or + – 0%
Group E – ++ or + 0%eCAM 2004;1(1) 23
Receptors for CAM Agents on NK Cells?
Control of the immune functions mediated by the nervous
system would be the major mechanism underlying NK cell
activation by physical CAM modalities (e.g. exercise, skin
rubdown and acupuncture) and psychological CAM ones
(e.g. relaxation, message therapy, music therapy and mirthful
laughter). On the other hand, numerous CAM agents have
also been reported to activate NK cell cytotoxity, improve
general health and reduce the risk of cancer development.
This type of phenomena, if real, should be understood as
reasonable if NK cells and/or some innate immune cells
expressed receptors for some components of various types of
CAM agents (e.g. liquid and food). Toll-like receptors and
receptors to lectins and β-glucan polysaccharides are the
most likely candidates responsible for NK cell activation
induced by intake-type CAM agents (100). These CAM-
agent receptors may well be preferentially expressed on
macrophages or dendritic cells. In such cases, these CAM-
agent-responding cells produce cytokines (e.g. type-I IFN,
IL-12 and IL-18), which induce NK cell activation.
Toll-like Receptors Involved?—Toll-like receptors (TLRs)
function as the pattern-recognition receptors in mammals
and play an essential role in their recognition of microbial
and fungal components (101–104). Ten members of the TLR
family have been identified in humans. TLRs activate NK-κB
and other signaling pathways, which results in the secretion
of various inflammatory cytokines (101–105). It has been
reported that TLR-2/6 recognize some components of
zymosan, but not β-glucan, which result in production of
cytokines and chemokines (106,107). Thus, TLRs might play
important roles in the biological effects of some intake-type
CAM agents. This is a very interesting subject for further
studies.
Receptors for Lectin Involved?—It has been established that
various members of the lectin family modify immunological
functions (108,109). Wild plants and fungi have traditionally
been the single largest source of lead lectin compounds for
the development of therapeutics agents by the pharmaceuti-
cal industry. Currently, mushroom and plant polysaccharides
are the focus of attention in relation to CAM, stimulating sci-
entific analysis and drug development to prevent and treat
cancer. Thus, some unknown C-type lectin-like receptors for
certain components of CAM agents and/or lectin, and lectin
interaction, might play roles in CAM effects.
Receptors for β-Glucan Involved?—The in vivo administra-
tion of β-glucan has been shown to potentiate host responses
against a variety of conditions, including tumor development
and infection (100,110,111). This has led to a number of clin-
ical trials using β-glucans for tumor immunotherapy with
some promising results. Thus, β-glucan receptors are one
likely class of receptors responsible for NK cell activation by
CAM agents.
The β-glucans are a heterogeneous group of glucose poly-
mers, consisting of a backbone of β(1→3)-linked β-D-gluco-
pyranosyl units with β(1→6)-linked side chains of varying
distribution and length. These polysaccharides are major cell
wall structural components in fungi, mushrooms, plants and
some bacteria. As they are not found in animals, these carbo-
hydrates are considered to be classic pattern-recognition
molecules (101) and are recognized by the innate immune
system. Vertebrate recognition of β-glucans appears to occur
exclusively via several cell surface receptors, and although
Figure 3. Summary of immune system control by autonomic nervous system. The central nervous and immune systems intimately crosstalk in the live body. In
particular, sympathetic nerves mediate inhibitory effects on NK cells. NK cell distribution and NK cell activity are controlled by autonomic nervous systems
directly and indirectly.24 CAM and NK cells
complement opsonization does contribute to the recognition
of particulate glucans, no plasma molecules recognizing this
carbohydrate structure have been identified. β-Glucan recog-
nition systems in invertebrates are completely different from
vertebrates (112); however, the recognition of β-glucan by
both systems results in the triggering of innate immunity
(Table 4).
β-Glucan receptor activity has subsequently been reported
on a variety of leukocytes, including macrophages, neutro-
phils, eosinophils and NK cells, as well as on non-immune
cells including endotherial cells, alveolar epithelial cells and
fibroblasts. Non-opsonic recognition of β-glucan by these
cells has been ascribed to multiple receptors (113), and
indeed a number of β-glucan receptors have been identified,
including CR3 (110), lactosylceramide (CDw17) (114),
scavenger receptors (115) and dectin-1 (116–118). Of these
receptors, however, dectin-1 has been clearly shown to play
a  role  in  mediating  the  biological  response  to  β-glucan
(119). Although the mechanisms are not yet fully understood,
the generation of the response starts at the cell surface and
requires a functional ITAM domain in cytoplasmic tails of
dectin-1. The ITAM motif becomes phosphorylated after
β-glucan binding, suggesting that signaling might occur in a
similar fashion to that of other ITAM-containing receptors,
such as NK-activating receptors and Fc receptors.
Not only β-glucan polysaccharides, but also oligosaccha-
rides have been reported as the effector components of some
CAM agents, which down-regulate production of immuno-
suppressive cytokines (100). It has been suggested that
glycochain, glycopeptide and glycolipid play a critical role
in numerous biological events, including immunological
responses (120–125). However, glycobiology still cannot
clearly reveal the molecular mechanisms for their biological
functions. Further analysis in glycobiology will identify the
crucial receptors for CAM on immune cells and elucidate the
essential molecules and mechanisms. As this field is rapidly
progressing, our perspective may be drastically changed in
several years. It will be interesting for us to present a revised
and expanded version of this review in a couple of years.
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